Since a group of pro-life plaintiffs first challenged the Food and Drug Administration’s approval of mifepristone, one of the two drugs used in chemical or medication abortions, the reporting on the case has been predictable.
Most of the news coverage of the legal threat to the “long-approved abortion pill” have focused only on the conservative credentials of the federal judge in Amarillo overseeing the case.
Very few have tried to explain the nature of the legal challenge, its merits and the health implications for women across the United States — which are significant.
